The Ross's Gull (Rhodostethia rosea) in North America

The population, distribution and range of the Ross's gull in North America remain poorly understood, as does almost every aspect of its ecology and biology. It breeds at a few disparate locations in the Canadian Arctic and is an annual fall migrant in northern Alaska where tens of thousands occur in the nearshore waters of the Beaufort and Chukchi Seas, but little else is known about the distribution, habitat requirements, migratory routes and wintering areas used by this species. In order to clarify the status of the Ross's gull in North America I sought to discover new breeding sites in the Canadian High Arctic in order to characterize nesting habitat requirements, develop a predictive model with which to identify suitable nesting habitat for Ross's gulls, and refresh outdated estimates of the number of individuals migrating past Point Barrow, Alaska. Taken together, my findings provide a comprehensive account of the current status of the Ross's gull in North America.

Che vinca il più Forte. Proposta di traduzione, analisi e commento di "Wojna polsko-ruska pod flagą biało-czerwoną" di Dorota Masłowska.

Traduzione dal polacco in italiano - accompagnata da analisi e commento dei temi proposti - di alcuni estratti dal bestseller della scrittrice polacca adolescente, che racconta il mondo visto dagli occhi di un giovane disoccupato poco istruito di provincia. Un'immagine cruda e senza filtri della gioventù in Polonia negli anni di transizione dalla caduta del muro di Berlino all'ingresso nell'Unione Europea. Un momento storico impossibile da collocare nella ripetitività tipica dei grandi avvenimenti in Polonia, vissuto direttamente sulla pelle dei suoi protagonisti, cioè i giovani senza né passato né futuro, incapaci di coltivare il presente.

Biological control of Sclerotinia sclerotiorum on beans in field by Trichoderma asperellum and Clonostachys rosea.

2009

Influência do óleo de nim no crescimento micelial, esporulação e viabilidade de Clonostachys rosea e Trichoderma harzianum.

2009

Redução do inóculo de Sclerotinia sclerotiorum por Trichoderma asperellum e Clonostachys rosea em feijão de inverno nas safras 2007 e 2008.

2009

Memory-enhancing effect of Rhodiola rosea L extract on aged mice

Purpose: The memory-enhancing effects of Rhodiola rosea L. extract (RRLE) on normal aged mice were assessed. Methods: In the open-field test, the effect of RRLE (150 and 300 mg/kg) on mouse locomotive activities was evaluated by investigating the extract’s influence on CAT and AchE activities in the brain tissue of mice. Results: Compared with aged group, high dose of RRLE reduced the total distance (3212.4 ± 123.1 cm, p < 0.05) significantly, increased catalase (CAT) activity (101.4 ± 12.2 U/mg pro, p < 0.05), and inhibited acetyl cholinesterase (AChE) activity (0.94 ± 0.12 U/mg pro, p < 0.05) in the brain tissue of aged mice. Conclusion: The results show that RRLE improves the memory functions of aged mice probably by increasing CAT activity while decreasing AChE activity.

Inibição do crescimento micelial de Sclerotinia sclerotiorum por filtrados de Trichoderma sp. e Clonostachys rosea.

Uma alternativa para controle do mofo-branco do feijão (Sclerotinia sclerotiorum, Ss) é o uso de agentes de controle biológico (ACB). Trichoderma sp. (Tr) e Clonostachys rosea (Cr) podem competir, parasitar e produzir metabólitos tóxicos contra fitopatógenos. Avaliou-se a capacidade de três isolados de Tr e um de Cr, previamente selecionados para o controle de Ss, em produzir metabólitos tóxicos contra o patógeno. Os ACB foram crescidos em caldo batata dextrose sob agitação (100 rpm) por sete dias. Após, o caldo foi filtrado a vácuo (membrana bacteriológica 0,22µm) e adicionou-se uma alíquota (2 ml) do filtrado ou de ADE (testemunha) a BDA fundente em placas de Petri. Após o resfriamento, adicionou-se no centro da placa um disco de micélio de Ss. As placas (cinco repetições/tratamento) foram incubadas a 20˚C ou 25˚C. Diariamente mediu-se o diâmetro das colônias até a testemunha atingir as bordas da placa. A 25˚C verificou-se significativa redução (Tukey, 5%) do crescimento micelial de Ss pelos filtrados dos três isolados de Tr (72 a 79%) e por Cr (50%). A 20ºC, apenas dois isolados de Tr inibiram Ss (45 a 65%). Os resultados indicam que os ACB podem atuar por antibiose, porém a eficiência é influenciada pelo ambiente.

Biological control of Sclerotinia sclerotiorum on beans in field by Trichoderma asperellum and Clonostachys rosea.

2008

Avaliação de isolados de Trichoderma sp. e Clonostachys rosea selecionados para o controle biológico de mofo-branco como agentes promotores de crescimento em feijoeiro.

2008

Controle biológico de Sclerotinia sclerotiorum em feijoeiro por isolados de Trichoderma sp. e Clonostachys rosea em campo.

2008

Efeito de extratos vegetais e óleos essenciais sobre Botrytis cinerea e o agente de biocontrole Clonostachys rosea.

2008

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma

The rapeutic options for malignant pleural mesothelioma (MPM) are limited despite the increasing incidence globally. The vinca alkaloid vinorelbine exhibits clinical activity; however, to date, treatment optimization has not been achieved using biomarkers. BRCA1 regulates sensitivity to microtubule poisons; however, its role in regulating vinorelbine-induced apoptosis in mesothelioma is unknown. Here we demonstrate that BRCA1 plays an essential role in mediating vinorelbine-induced apoptosis, as evidenced by (1) the strong correlation between vinorelbine sensitivity and BRCA1 expression level; (2) induction of resistance to vinorelbine by BRCA1 using siRNA oligonucleotides; (3) dramatic down-regulation of BRCA1 following selection for vinorelbine resistance; and (4) the re-activation of vinorelbine-induced apoptosis following re-expression of BRCA1 in resistant cells. To determine whether loss of BRCA1 expression in mesothelioma was potentially relevant in vivo, BRCA1 immunohistochemistry was subsequently performed on 144 primary mesothelioma specimens. Loss of BRCA1 protein expression was identified in 38.9% of samples. Together, these data suggest that BRCA1 plays a critical role in mediating apoptosis by vinorelbine in mesothelioma, warranting its clinical evaluation as a predictive biomarker. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Advances in the systemic therapy of malignant pleural mesothelioma

Malignant pleural mesothelioma is an aggressive thoracic malignancy associated with exposure to asbestos, and its incidence is anticipated to increase during the first half of this century. Chemotherapy is the mainstay of treatment, yet sufficiently robust evidence to substantiate the current standard of care has emerged only in the past 5 years. This Review summarizes the evidence supporting the clinical activity of chemotherapy, discusses the use of end points for its assessment and examines the influence of clinical and biochemical prognostic factors on the natural history of malignant pleural mesothelioma. Early-phase clinical trials of second-line and novel agents are emerging from an increased understanding of mesothelioma cell biology. Coupled with high-quality translational research, such developments have real potential to improve the outlook of patients at a time of increasing incidence.

Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer : a review of the existing clinical trials and results of the expanded access programme in the UK

Trastuzumab is a humanised monoclonal antibody against the extracellular domain of HER2 (human epidermal growth factor receptor-2) that is overexpressed in about 25% of human breast cancers. It has shown clinical benefit in HER2-positive breast cancer cases when used alone or in combination with chemotherapy. Trastuzumab increases the response rate to chemotherapy and prolongs survival when used in combination with taxanes. In this article, we review the clinical trials where trastuzumab has been administered together with docetaxel, and we present the results of the trastuzumab expanded access programme (EAP) in the UK. Combination of trastuzumab with docetaxel results in similar response rates and time-to-progression with the trastuzumab/paclitaxel combinations. The toxicity of the combination and the risk of heart failure are low. The clinical data for the docetaxel/trastuzumab combination indicate a favourable profile from both the efficacy and the safety point of view and confirm the feasibility and safety of trastuzumab administration both as monotherapy and in combination with docetaxel. © 2004 Blackwell Publishing Ltd.

Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy

Purpose: The development of liver metastases from breast cancer is associated with a very poor prognosis, estimated at 4 months median survival. Since treatment with many chemotherapeutic agents is relatively contraindicated, we assessed the safety, tolerability and potential efficacy of combination chemotherapy with vinorelbine and cisplatin (ViP). Method: Pilot study in 11 patients with histologically confirmed breast carcinoma, radiological evidence of liver metastases and serum bilirubin greater than 1.5 times the upper limit of normal. Patients received up to six cycles of cisplatin (75 mg/m 2) every 21 days and vinorelbine (20 mg/m 2) on days 1 and 8 of every 21-day cycle. Measurement of liver lesions was performed on CT scan every 8 weeks into treatment. Results: The most frequently reported adverse event was myelosuppression. Other adverse effects included nausea, vomiting and mild neurotoxicity. Two patients died after one treatment with ViP, one of whom suffered an intracerebral haemorrhage that was possibly treatment-related. Improvement in liver function tests was observed in 10 patients, and mean time to normalization of bilirubin levels was 36 days. Partial responses were documented radiologically in 7 out of 11 patients treated. Median overall survival from trial entry was 6.5 months (range 11-364 days), with one patient alive 13 months from trial entry. Conclusion: Normalization of liver function is possible with ViP treatment of metastatic breast cancer, offering the potential to prolong survival. Phase II clinical trials of this regimen in this patient group should include measurement of quality of life in order to assess risk versus benefit.